Advanced/Metastatic Clear Cell Renal Cell Carcinoma

Oncology
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Arsenal Biosciences
Arsenal BiosciencesCA - South SF
1 program
1
AB-2100Phase 1/21 trial
Active Trials
NCT06245915Active Not RecruitingEst. Jun 2028
Allogene Therapeutics
Allogene TherapeuticsSOUTH SAN FRANCISCO, CA
1 program
1
ALLO-316Phase 11 trial
Active Trials
NCT04696731Active Not RecruitingEst. Dec 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Arsenal BiosciencesAB-2100
Allogene TherapeuticsALLO-316

Clinical Trials (2)

AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)

Start: Feb 2024Est. completion: Jun 2028
Phase 1/2Active Not Recruiting

Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Start: Feb 2021Est. completion: Dec 2025
Phase 1Active Not Recruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space